David Tsao

BillionToOne Is Solving One of Biotech’s Hardest Problems

Jared Friedman, David Tsao, Oguzhan Atay

Billion to One, founded by PhD students Oguzhan and David, leverages proprietary synthetic DNA methods to detect rare cell-free DNA variations for prenatal screening and cancer liquid biopsies. Since its public listing with a valuation over $4 billion, the company has scaled its automated facility to process 600,000 tests annually and launched North Star Select for late-stage cancer treatment guidance. The firm now executes a strategic roadmap to address early-stage cancers through a capital-efficient progression from commercial adoption to population-wide screening, aiming to significantly reduce cancer mortality rates.